Advanced Flower Capital (NASDAQ:AFCG) announced its fourth-quarter and full-year 2025 financial results on Wednesday, marking the conclusion of its transformation into a business development company.
Ocugen (NASDAQ:OCGN), a Malvern, Pennsylvania-based clinical-stage biotechnology company developing modifier gene therapies for ophthalmic and other diseases, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, alongside a business update highlighting progress across its three lead modifier gene therapy programs.
Caesarstone (NASDAQ:CSTE), a global pioneer in quartz and porcelain surfaces, reported a fourth-quarter net loss of $87.9 million, or $2.55 per share, as it finalized major components of its multi-year strategic transformation.
Republic Airways Holdings (NASDAQ:RJET) concluded a "transformational" fiscal year 2025 by swinging to a full-year profit of $76.2 million, or $1.87 per share.
Altisource Portfolio Solutions (NASDAQ:ASPS) reported fiscal 2025 results on Wednesday, marking a return to full-year profitability as the company navigates a stabilizing residential real estate market.
Brown-Forman (NYSE:BFA) announced fiscal third-quarter profit of $267 million, or 58 cents per diluted share, comfortably beating the Zacks Consensus Estimate of 48 cents.
Cellectar Biosciences (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company specializing in radioconjugates, reported a significantly reduced net loss for 2025 as it transitioned its lead program, iopofosine I-131, into the final regulatory stages.
Nexxen International (NASDAQ:NEXN), a global ad-tech platform specializing in data and advanced TV, announced record financial results for the fiscal year ended December 31, 2025.
Holley (NYSE:HLLY), the definitive market leader in the high-performance automotive aftermarket, reported a robust finish to fiscal year 2025, swinging to a net profit following a challenging prior year.
Daktronics (NASDAQ:DAKT) posted fiscal third-quarter results that outpaced the prior year across nearly every financial metric, fueled by efficient backlog conversion and stabilized supply chains.
Abercrombie & Fitch (NYSE:ANF) reported record-breaking financial results for fiscal 2025 on Wednesday, as the teen-focused Hollister brand propelled the retailer to its highest annual sales in company history despite a slight cooling at its namesake brand.
EyePoint Pharmaceuticals (NASDAQ:EYPT) entered a critical catalyst year on Wednesday, reporting full-year 2025 results and a clinical roadmap that places its lead candidate, DURAVYU, on track for its first pivotal Phase 3 readout in just months.
